万征,党群

• 1:天津医科大学总医院
• 2:天津市南开医院

摘要(Abstract)：

<正>药物洗脱支架(DES)和有效的药物治疗降低了再狭窄率,提高了血运重建率,但对降低临床血栓事件的效果并未确定,抗血小板药物疗程却只增不减[1]。2006年一项观察停用氯比格雷对DES和裸金属支架(BMS)晚期事件影响研究(BASKET-LATE)报告,停药使DES相关的晚期血栓形成,增加了死亡或非致死性心肌梗死(MI)的发生率[2]。随后研究也显示,DES后服用12个月或以上的阿司匹林和氯吡格雷双联抗血小板治疗(DAPT)有益于防治支架相关的血栓形

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 万征,党群

参考文献(References)：

• [1]Kirtane AJ,Gupta A,Iyengar S,et al.Safety and efficacy of drug-eluting and bare metal stents:comprehensive meta-analysis of randomized trials and observational studies.Circulation,2009,119:3198-3206.
• [2]Pfisterer M,Brunner-La Rocca HP,Buser PT,et al.Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:an observational study of drug-eluting versus bare-metal stents.J Am Coll Cardiol,2006,48:2584-2591.
• [3]Camenzind E,Steg PG,Wijns W.Stent thrombosis late after implantation of first-generation drug-eluting stents:a cause for concern.Circulation,2007,115:1440-1455.
• [4]中华医学会心血管病学分会中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009).中华心血管病杂志,2009,37:4-25.
• [5]Grines CL,Bonow RO,Casey DEJ,et al.Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:a science advisory from the American Heart Association,American College of Cardiology,Society for Cardiovascular Angiography and Interventions,American College of Surgeons,and American Dental Association,with representation from the American College of Physicians.J Am Coll Cardiol,2007,49:734-739.
• [6]Pant S,Neupane P,Ramesh KC,et al.Post percutaneous coronary intervention antiplatelet therapy:current perceptions,prospects and perplexity.Cardiol J,2011,18:712-717.
• [7]Park SJ,Park DW,Kim YH,et al.Duration of dual antiplatelet therapy after implantation of drug-eluting stents.N Engl J Med,2010,362:1374-1382.
• [8]Valgimigli M,Campo G,Monti M,et al.Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting:a randomized multicenter trial.Circulation,2012,125:2015-2026.
• [9]Zhang T,Shen L,Hu L,et al.Optimal Duration of Dual-Antiplatelet Therapy Following Drug-Eluting Stent Implantation:A Meta-Analysis.J Clin Pharmacol,2012,25.
• [10]Gwon HC,Hahn JY,Park KW,et al.Six-month versus12-month dual antiplatelet therapy after implantation of drug-eluting stents:the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting(EXCELLENT)randomized,multicenter study.Circulation,2012,125:505-513.
• [11]Tada T,Natsuaki M,Morimoto T,et al.Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation:landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.Circ Cardiovasc Interv,2012,5:381-391.
• [12]Nakagawa T,Hiasa Y,Hosokawa S,et al.The potential benefits and risks of the use of dual antiplatelet therapy beyond6months following sirolimus-eluting stent implantation for low-risk patients.J Cardiol,2011,57:283-289.
• [13]Kang KW,Kim BK,Jang JY,et al.Comparison of three-year clinical outcomes with nonextended versus extended dual antiplatelet therapy between first-and second-generation drug-eluting stent implantation in patients with acute myocardial infarction:data from the infarct prognosis study registry.J Interv Cardiol,2012,25:245-252.
• [14]Alli O,Smith C,Hoffman M,et al.Incidence,predictors,and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel.J Clin Gastroenterol,2011,45:410-414.
• [15]Musumeci G,Rossini R,Lettieri C,et al.Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.Catheter Cardiovasc Interv,2012,80:395-405.
• [16]Musumeci G,Di Lorenzo E,Valgimigli M.Dual antiplatelet therapy duration:what are the drivers?Curr Opin Cardiol,2011,26Suppl1:S4-S14.
• [17]Kandzari DE,Barker CS,Leon MB,et al.Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.JACC Cardiovasc Interv,2011,4:1119-1128.
• [18]Han Y,Jing Q,Li Y,et al.Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in″real-world″practice:three-year outcomes of the CREATE(Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents)study.Catheter Cardiovasc Interv,2012,79:211-216.
• [19]http://www.ccheart.com.cn/ccheart_cit2012/a/huiyi/2012/0316/67.html.
• [20]http://www.abbott.com/news-media/press-releases/abbotts-xience-prime-and-xience-v-drug-eluting-stents-receive-indication-in-europe-for-minimum-th.htm.
• [21]http://www.cscnet.org.cn/2012/cn/abstract_search.asp.
• [22]Hahn JY,Song YB,Choi JH,et al.Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents:the DATE(Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent)registry.Circ J,2010,74:2314-2321.
• [23]Cassese S,De Luca G,Villari B,et al.Reduced antiplatelet therapy after drug-eluting stenting:multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for2or6months-MATRIX study.Catheter Cardiovasc Interv,2012,80:408-416.
• [24]Damman P,Klomp M,Silber S,et al.Duration of dual antiplatelet therapy and outcomes after coronary stenting with the Genous?bio-engineered R stent?in patients from the e-HEALING registry.Catheter Cardiovasc Interv,2012,79:243-252.
• [25]Sardella G,Mancone M,Biondi-Zoccai G,et al.Beneficial Impact of Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation.J Interv Cardiol,2012,16.
• [26]Kastrati A,Byrne RA,Schulz S.Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation?JACC Cardiovasc Interv,2011,4:1129-1132.